What is HC Wainwright’s Estimate for INKT FY2026 Earnings?

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Equities research analysts at HC Wainwright increased their FY2026 earnings estimates for MiNK Therapeutics in a research report issued on Wednesday, November 11th. HC Wainwright analyst M. Keller now anticipates that the company will post earnings of ($2.29) per share for the year, up from their prior forecast of ($2.58). HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.53) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q4 2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($0.64) EPS.

A number of other research firms have also issued reports on INKT. B. Riley Financial restated a “buy” rating and issued a $50.00 target price (up from $43.00) on shares of MiNK Therapeutics in a report on Wednesday, October 21st. Zacks Research downgraded MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, MiNK Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $44.00.

MiNK Therapeutics Trading Down 6.8%

NASDAQ INKT opened at $9.53 on Friday. The firm’s 50 day moving average price is $11.14 and its two-hundred day moving average price is $11.21. MiNK Therapeutics has a twelve month low of $8.48 and a twelve month high of $16.93.

MiNK Therapeutics (NASDAQ:INKT) last issued its quarterly earnings results on Wednesday, November 11th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.16. The firm had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.07 million.

Insider Buying and Selling at MiNK Therapeutics

In other news, CEO Jennifer Buell sold 6,938 shares of the stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the sale, the chief executive officer directly owned 74,195 shares of the company’s stock, valued at $783,499.20. This represents a 8.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 20.40% of the stock is owned by corporate insiders.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses. MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.